PAK1 inhibition promotes vascular normalisation and an immune-permissive tumour microenvironment (TME), whereas PAK4 inhibition enhances gemcitabine response by increasing vessel calibre and downregulating DNA repair pathways. This evidence concerns the gene PAK1 and neoplasm.